Vecuronium: Difference between revisions
(Created page with "==General== *Type: *Dosage Forms: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Pregnancy Rating: *Lac...") |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (13 intermediate revisions by 6 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: [[Neuromuscular blocker]], nondepolarizing, fast | ||
*Dosage Forms: | *Dosage Forms: IV | ||
*Common Trade Names: | *Common Trade Names: Norcuron | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Not recommended for [[RSI]] | |||
*0.15mg/kg IV based on ideal body weight, can prime with 0.01mg/kg IV | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Not recommended for [[RSI]] | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C | ||
*Lactation: | *Lactation: Infant risk cannot be ruled out | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
**Pediatric | **Pediatric | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult | ||
**Pediatric | **Pediatric | ||
| Line 23: | Line 26: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*[[Anaphylaxis]] | |||
===Common=== | ===Common=== | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: Varies, from 30-60 minutes | ||
*Metabolism: | *Metabolism: Hepatic | ||
*Excretion: | *Excretion: Renal | ||
*Mechanism of Action: | *Mechanism of Action: Non-depolarizing neuromuscular blocking agent. Long duration with slow onset. Competes for cholinergic receptors at the motor end-plate. [[Acetylcholinesterase inhibitors]] like those found in organophosphates antagonize this action | ||
==Indications by Condition== | |||
''The following table is automatically generated from disease/condition pages across WikEM.'' | |||
{{#ask:[[Has DrugName::Vecuronium]] | |||
|?Has Indication=Indication | |||
|?Has Dose=Dose | |||
|?Has Context=Context | |||
|?Has Route=Route | |||
|?Has Population=Population | |||
|format=table | |||
|headers=plain | |||
|mainlabel=- | |||
|sort=Has Indication | |||
|limit=50 | |||
}} | |||
==See Also== | ==See Also== | ||
*[[Critical care quick reference]] | |||
*Reversal agent: [[Sugammadex]] | |||
== | ==References== | ||
Micromedex | |||
<references/> | <references/> | ||
[[Category: | [[Category:Pharmacology]] | ||
[[Category:Critical Care]] | |||
Latest revision as of 21:58, 20 March 2026
General
- Type: Neuromuscular blocker, nondepolarizing, fast
- Dosage Forms: IV
- Common Trade Names: Norcuron
Adult Dosing
- Not recommended for RSI
- 0.15mg/kg IV based on ideal body weight, can prime with 0.01mg/kg IV
Pediatric Dosing
- Not recommended for RSI
Special Populations
- Pregnancy Rating: C
- Lactation: Infant risk cannot be ruled out
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: Varies, from 30-60 minutes
- Metabolism: Hepatic
- Excretion: Renal
- Mechanism of Action: Non-depolarizing neuromuscular blocking agent. Long duration with slow onset. Competes for cholinergic receptors at the motor end-plate. Acetylcholinesterase inhibitors like those found in organophosphates antagonize this action
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Rapid sequence intubation | 0.1 mg/kg | Paralytic | IV | Adult |
See Also
- Critical care quick reference
- Reversal agent: Sugammadex
References
Micromedex